POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium is the major intracellular cation; it maintains intracellular tonicity, transmits nerve impulses, and contracts muscles. Dextrose provides calories and may reduce protein and nitrogen loss. Sodium chloride maintains extracellular fluid volume and tonicity.
| Metabolism | Potassium is excreted primarily by the kidneys; dextrose is metabolized to carbon dioxide and water; sodium chloride is excreted mainly by the kidneys. |
| Excretion | Renal: >90% of potassium, dextrose (metabolized), and sodium are eliminated renally. Potassium is primarily excreted by the kidneys (90-95%) with a small fraction (5-10%) eliminated in feces. Dextrose is completely metabolized to carbon dioxide and water, with no significant biliary excretion. Sodium is excreted mainly in urine (>95%) with minimal fecal loss. |
| Half-life | Potassium: 7.5 hours (distribution) with terminal half-life dependent on renal function; in normal renal function, effective half-life for potassium homeostasis is ~4-6 hours. Dextrose: Immediate metabolism; not applicable. Sodium: 12-24 hours (renal handling) but varies with sodium balance. |
| Protein binding | Potassium: Not significantly protein-bound (<2%). Dextrose: Not protein-bound. Sodium: Not protein-bound (<5% bound to albumin). |
| Volume of Distribution | Potassium: 0.67 L/kg (total body water); clinical meaning: distributes throughout extracellular and intracellular compartments, but intracellular uptake is slow. Dextrose: 0.2 L/kg (extracellular fluid). Sodium: 0.25 L/kg (extracellular fluid). |
| Bioavailability | Intravenous: 100% for all components. Oral (not applicable for this formulation): N/A. IM/SC: Not recommended due to irritation. |
| Onset of Action | Intravenous: Immediate; potassium effects on membrane potential occur within minutes. Dextrose: Onset of caloric effect within minutes. Sodium: Onset of volume expansion within minutes. |
| Duration of Action | Potassium: Duration of supplementation is 4-6 hours depending on infusion rate and renal function; continuous infusion required for sustained effect. Dextrose: Duration of glucose elevation is short-lived (1-2 hours) due to rapid insulin release. Sodium: Duration depends on volume status; excess sodium is excreted over 12-24 hours. |
| Molecular Weight | 74.55 |
Intravenous infusion; rate determined by clinical need; typical adult maintenance: 100-200 mL/hour (equivalent to KCl 0.15 g/hour, dextrose 10 g/hour, sodium chloride 0.2 g/hour) based on fluid and electrolyte requirements; maximum infusion rate: KCl 10 mEq/hour (0.75 g/hour) or 200 mL/hour, whichever is lower; do not exceed 200 mL/hour.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <30 mL/min: Avoid use due to risk of hyperkalemia and fluid overload; consider alternative therapy. GFR 30-50 mL/min: Use with caution, reduce infusion rate by 50% and monitor serum potassium and renal function closely. GFR >50 mL/min: No adjustment required. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Use with caution; reduce infusion rate by 25-50% and monitor serum potassium and ammonia levels. Child-Pugh Class C: Avoid use; risk of hyperkalemia and precipitation of hepatic encephalopathy. |
| Pediatric use | Weight-based: Infuse at 0.5-1 mL/kg/hour (equivalent to KCl 0.75-1.5 mg/kg/hour, dextrose 0.5-1 g/kg/hour, sodium chloride 1-2 mg/kg/hour); maximum rate: 2 mL/kg/hour; adjust based on serum electrolytes, glucose, and fluid status. Not recommended for neonates due to high dextrose concentration (10%) unless under strict monitoring. |
| Geriatric use | Initiate at lower end of dosing range (e.g., 50-100 mL/hour) due to decreased renal function and higher risk of electrolyte imbalances and fluid overload; monitor serum potassium, glucose, and renal function frequently; avoid in patients with heart failure or significant renal impairment (GFR <30 mL/min). |
| 1st trimester | Generally considered safe when used at recommended doses for correction of hypokalemia. Potassium crosses placenta to maintain fetal electrolyte balance. No increased risk of major malformations reported. |
| 2nd trimester | Safe for use at recommended doses. Monitor serum potassium levels closely to avoid hyperkalemia, which can affect fetal cardiac function. |
| 3rd trimester | Safe with careful monitoring. Avoid excessive potassium administration to prevent maternal hyperkalemia, which may cause fetal bradycardia or arrhythmias. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium crosses the placenta freely via active transport and diffusion to maintain fetal electrolyte homeostasis. Fetal serum potassium levels are similar to maternal levels. |
| Breastfeeding | Potassium is a normal constituent of breast milk. Exogenous potassium enters milk but is unlikely to affect breastfed infant due to renal homeostatic mechanisms. Use with caution in mothers with renal impairment or hyperkalemia. |
| Lactation Rating | L1 (Compatible) |
| Teratogenic Risk | First trimester: Potassium chloride at usual replacement doses is not associated with major malformations. Dextrose may be given as needed for maternal hypoglycemia but high doses near delivery may cause neonatal hypoglycemia. Sodium chloride at typical replacement doses is not teratogenic. Second and third trimesters: Potassium chloride is safe; however, avoid hyperkalemia as it may cause maternal cardiac effects. Dextrose infusion may cause maternal hyperglycemia and subsequent fetal hyperinsulinemia leading to neonatal hypoglycemia. Sodium chloride excess can contribute to fluid overload and hypertension. Overall, no directly teratogenic risk from these components at standard therapeutic doses. |
| Fetal Monitoring | Maternal: Serum electrolytes (potassium, sodium), glucose, fluid balance, urine output, cardiac monitoring if rapid infusion; fetal: heart rate monitoring if maternal hyperglycemia occurs; ultrasound for growth if prolonged use. |
| Fertility Effects | No known adverse effects on fertility from potassium chloride, dextrose, or sodium chloride at therapeutic doses. Unlikely to impact reproductive function. |
■ FDA Black Box Warning
Potassium chloride injection concentrate must be diluted and used only in patients with severe hypokalemia; rapid infusion can cause fatal hyperkalemia.
| Common Effects | fluid replacement |
| Serious Effects |
Hyperkalemia (serum potassium >5.5 mEq/L)Severe renal impairment (e.g., anuria, oliguria) with reduced potassium excretionPotassium-sparing diuretic therapy (e.g., spironolactone, eplerenone) unless closely monitoredConcomitant use of ACE inhibitors or ARBs with significant hyperkalemia riskAdrenal insufficiency (e.g., Addison's disease) due to impaired potassium excretion
| Precautions | Risk of hyperkalemia, especially in patients with renal impairment or those receiving potassium-sparing diuretics, Do not administer unless solution is clear and container undamaged, Use with caution in patients with heart failure, severe renal insufficiency, or conditions predisposing to hyperkalemia, Monitor serum electrolytes, glucose, and fluid balance |
| Food/Dietary | Avoid potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, salt substitutes) unless directed by your healthcare provider, as this product contains potassium. Limit high-sodium foods if hypertensive. Monitor carbohydrate intake if diabetic. |
| Clinical Pearls | Monitor serum potassium, glucose, and sodium levels during infusion, especially in patients with renal impairment, diabetes, or heart failure. Use with caution in patients with hyperkalemia, severe renal failure, or hyperglycemia. Infuse via central line if concentration > 0.15% KCl due to risk of phlebitis. Check compatibility with other IV additives. |
| Patient Advice | This medication is used to replace fluids, sugar, and electrolytes in your body. · Tell your healthcare provider if you have kidney disease, diabetes, heart disease, or high blood pressure. · Report any symptoms like chest pain, irregular heartbeat, trouble breathing, or swelling of your hands/feet. · Do not suddenly stop receiving this infusion without medical advice. · Notify your nurse if you experience pain, redness, or swelling at the IV site. |
Loading safety data…